Opinion|Videos|February 14, 2025
MCL Therapy Selection and Sequencing
Panelists discuss the treatment- and patient-specific factors considered when determining induction therapy for treatment-naive patients with mantle cell lymphoma (MCL), including the decision between aggressive and less aggressive approaches, and how prior therapy exposure influences subsequent treatment sequencing for MCL.
Advertisement
Episodes in this series
- What treatment- and patient-specific factors do you consider when determining induction therapy for a treatment-naive patient with MCL (eg, aggressive vs less aggressive)?
- How do you sequence therapies for patients with MCL and how does prior therapy exposure influence your subsequent choice of treatments?
Advertisement
Related to this article
CMS' rule ending Medicaid and CHIP funding for pediatric sex-rejecting procedures is now in effect.
At a roundtable in Cleveland, kidney experts said IgA nephropathy and FSGS often go unrecognized, calling for EHR flags and better referral channels.
Labial gland biopsy may support diagnosis of neurologic Sjögren disease, especially when antibody tests are negative or inconclusive.
This analysis in RR MCL shows CAR T-cell therapy (brexucabtagene) yields higher complete responses vs bispecific antibodies; durability remains unclear.
Meta-analysis finds oral JAK inhibitors like baricitinib and ritlecitinib drive strong alopecia areata hair regrowth, improving SALT scores with manageable safety.
Follitropin delta yields cumulative ongoing pregnancy in 64.0% of patients under 35 and 43.9% of those 35 to 42 in 2 placebo-controlled IVF trials.
The Ambulatory Specialty Model aims to reduce chronic disease costs by mandating specialist participation and tying payments to quality and cost, while posing nationwide risk challenges.
Medicare drug price negotiations lowered out-of-pocket costs for some beneficiaries, but those reaching the annual Part D cap saw no direct savings.
Advertisement
Advertisement
Trending on AJMC
1
Medicare Drug Price Negotiations Yield Uneven Out-of-Pocket Savings
2
CMS Rule Ends Medicaid, CHIP Funding for Pediatric Gender Care
3
Rusfertide Keeps Working Where Hydroxyurea Fades: Andrew Kuykendall, MD
4
Oral JAK Inhibitors Boost Hair Regrowth Odds in Alopecia Areata
5